Centrum Broking gives 'buy' call for Vijaya Diagnostic, Granules India
Brokerage house Centrum Broking has given a 'buy' call for Vijaya Diagnostic Centre and Granules India stocks09-02-2022
09-02-2022
Earnings Call for Q3FY22 of Granules India
Conference Call with Granules India Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.08-02-2022
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for Q3 of FY2208-02-2022
GRANULES INDIA LTD.-$ - 532482 - Fixed Record Date As 18Th February, 2022 For Payment Of Third Interim Dividend Of FY22
Fixed record date as 18th February, 2022 for payment of Third Interim Dividend FY2208-02-2022
GRANULES INDIA LTD.-$ - 532482 - Board declares Third Interim Dividend
Granules India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 08, 2022, inter alia, has declared third interim dividend of 25 paise per share of face value of Re. 1/- each representing 25% of paid-up capital for the financial year 2021-22.08-02-2022
Q3FY22 Quarterly Result Announced for Granules India Ltd.
Pharmaceuticals company Granules India announced Q3FY22 results: Revenue for Q3FY22 stood at Rs 997 crore, growth of 18% YoY. FD segment grew by 8%, PFI grew by 32% and API 24% when compared to YoY. Increase in Paracetamol across all the segments by Rs 108 crore and increase in other molecules by Rs 56 crore in view of steady market capture by newly launched molecules. For the consecutive two quarters, revenue share of other molecules maintained at 19%. Revenue from Europe increased to 24.5% when compared to 18.6% YoY on account of increase in selling prices for Paracetamol. The overall gross margin recorded is lower in % terms due to change in Segment mix in the total revenue. Share of Finished dosage has come down from 57% in Q2 to 46% in Q3 due to higher inventory build-up at USA and year end. EBITDA stood at Rs 174 crore, down by 17.9% YoY. EBITDA margins stood at 17.4% compared to 25.1%. PAT at Rs 101 crore, down by 31.3%, driven by reduction in Gross margin and increase in Freight cost by Rs 29 crore on account of shortage of containers and increase in R&D; cost by Rs 13 crore as part of our future growth strategy. During the quarter we filed two ANDA, two Canadian Dossiers, one US DMF, one CEP and received three ANDA approvals. The Board of Directors has declared its third interim dividend of 25 paise per equity share of INR 1/- each. Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “I am pleased to share that we are slowly getting back to the normal as is evident from the revenue growth which came in despite the continuing disruptions and challenging environment such as raw material price increase, unstable supply from China and PAP supply constraints. We expect the situation to improve in coming quarters and remain focused on execution and agile to the market opportunities. We at Granules are now ready to take a leap to transform our business to the next level. We are strengthening management capabilities and are investing in R&D; infrastructure, scientific talent, and partnerships in science & technology which will lead to sustainability, leadership, backward integration and focus on quality of our portfolio. Our initiatives will bring in the triple bottom line in the form of social, environmental, and financial advantages resulting in a greater stakeholder’s value.” Result PDF08-02-2022
GRANULES INDIA LTD.-$ - 532482 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting08-02-2022
GRANULES INDIA LTD.-$ - 532482 - Unaudited Financial Results For The Quarter Ended December 31,2021.
Unaudited Financial Results for the quarter ended December 31,2021.08-02-2022
Granules India gets USFDA nod for generic antidepressant drug
Granules Pharmaceuticals, Inc (GPI), a wholly-owned subsidiary of the company, has received approval from the US Food Drug Administration (USFDA) to market the product in strengths of 150 mg and 300 mg, the Hyderabad-based drug firm said in a statement.03-02-2022
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Earnings Conference call for Q3, FY 2021-2203-02-2022